Overview

Safety Study of Tivanisiran to Treat Dry Eye

Status:
Recruiting

Trial end date:
2023-10-24

Target enrollment:

Participant gender:

Summary

This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).

Phase:

Phase 3

Details

Lead Sponsor:

Sylentis, S.A.

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions